A cross-talk between NFAT and NF-κB pathways is crucial for nickel-induced COX-2 expression in Beas-2B cells.

Abstract:

:Cyclooxygenase-2 (COX-2) is a critical enzyme implicated in chronic inflammation-associated cancer development. Our studies have shown that the exposure of Beas-2B cells, a human bronchial epithelial cell line, to lung carcinogenic nickel compounds results in increased COX-2 expression. However, the signaling pathways leading to nickel-induced COX-2 expression are not well understood. In the current study, we found that the exposure of Beas-2B cells to nickel compounds resulted in the activation of both nuclear factor of activated T cell (NFAT) and nuclear factor-κB (NF-κB). The expression of COX-2 induced upon nickel exposure was inhibited by either a NFAT pharmacological inhibitor or the knockdown of NFAT3 by specific siRNA. We further found that the activation of NFAT and NF-κB was dependent on each other. Since our previous studies have shown that NF-κB activation is critical for nickel-induced COX-2 expression in Beas-2B cells exposed to nickel compounds under same experimental condition, we anticipate that there might be a cross-talk between the activation of NFAT and NF-κB for the COX-2 induction due to nickel exposure in Beas-2B cells. Furthermore, we showed that the scavenging of reactive oxygen species (ROS) by introduction of mitochondrial catalase inhibited the activation of both NFAT and NF-κB, and the induction of COX-2 due to nickel exposure. Taken together, our results defining the evidence showing a key role of the cross-talk between NFAT and NF-κB pathways in regulating nickel-induced COX-2 expression, further provide insight into the understanding of the molecular mechanisms linking nickel exposure to its lung carcinogenic effects.

authors

Cai T,Li X,Ding J,Luo W,Li J,Huang C

doi

10.2174/156800911795656001

subject

Has Abstract

pub_date

2011-06-01 00:00:00

pages

548-59

issue

5

eissn

1568-0096

issn

1873-5576

pii

EPub-Abstract-CCDT-132

journal_volume

11

pub_type

杂志文章
  • Autophagy as a Potential Therapeutic Target in Breast Cancer Treatment.

    abstract::One of the crucial reasons of breast cancer therapy failure is an impairment of mechanisms responsible for metabolism and cellular homeostasis, which makes it difficult to foresee the response to the treatment. Targeted therapy in breast cancer is dictated by the expression of specific molecules such as growth factor ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009617666171114143330

    authors: Lisiak N,Toton E,Rybczynska M

    更新日期:2018-01-01 00:00:00

  • Effects of Iron Chelation in Osteosarcoma.

    abstract:BACKGROUND:Osteosarcoma is an aggressive bone tumor. Itrepresents the principal cause of cancer-associated death in children.Considering the recent findings on the role of iron in cancer, iron chelation has been investigated for its antineoplastic properties in many tumors. Deferasirox is the most used iron chelator co...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/1568009620666201230090531

    authors: Argenziano M,Di Paola A,Tortora C,Di Pinto D,Pota E,Di Martino M,Perrotta S,Rossi F,Punzo F

    更新日期:2020-12-29 00:00:00

  • Cathepsin D as a Promising Target for the Discovery of Novel Anticancer Agents.

    abstract:BACKGROUND:Cathepsin D (CATD), one of the aspartyl endoproteinase involved in different physiological processes and signaling pathways, is accountable for metabolic breakdown of intracellular proteins, the activation of growth factors, hormones, and precursors of enzyme, the processing of antigens, enzyme inhibitors an...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009616666161229145115

    authors: Dubey V,Luqman S

    更新日期:2017-01-01 00:00:00

  • Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target?

    abstract::Although the imatinib based therapy of chronic myeloid leukemia (CML) represents a triumph of medicine, not all patients with CML benefit from this drug due to the development of resistance and intolerance. The interruption of imatinib treatment is often followed by clinical relapse, suggesting a failure in the killin...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/15680096113139990083

    authors: Adamia S,Pilarski PM,Bar-Natan M,Stone RM,Griffin JD

    更新日期:2013-09-01 00:00:00

  • Obesity-enhanced colon cancer: functional food compounds and their mechanisms of action.

    abstract::Obesity is rapidly becoming a global phenomenon. This is more than a cosmetic issue as obesity is associated with several life-threatening diseases, including colon cancer. Insulin resistance and inflammation, underlying factors in obesity-related diseases, promote colonocyte proliferation and suppress programmed cell...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800908786241087

    authors: Vanamala J,Tarver CC,Murano PS

    更新日期:2008-11-01 00:00:00

  • Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia.

    abstract::Heat shock proteins (HSPs) are molecular chaperones that stabilize folding and conformation of normal as well as oncogenic proteins. These chaperones thereby prevent the formation of protein aggregates. HSPs are often overexpressed in human malignancies, including AML. HSP90 is the main chaperon required for the stabi...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800909789271486

    authors: Reikvam H,Ersvaer E,Bruserud O

    更新日期:2009-09-01 00:00:00

  • Pharmacogenomics opportunities in nuclear receptor targeted cancer therapy.

    abstract::Nuclear Hormone Receptors (NR) represent one of the most promising protein families in terms of therapeutic applications. These transcription factors are naturally switched on and off by small molecule hormones presenting physico-chemical properties very similar to therapeutic chemical entities. NRs represent therefor...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009023333845

    authors: Schapira M

    更新日期:2002-09-01 00:00:00

  • Insight into Discovery of Next Generation Reversible TMLR Inhibitors Targeting EGFR Activating and Drug Resistant T790M Mutants.

    abstract:BACKGROUND:Epidermal growth factor receptor (EGFR) is a well-recognised drug target exploited for treating non-small cell lung cancer (NSCLC). Gefitinib and erlotinib are first generation clinically employed inhibitors used against EGFR activating mutants. However, during course of treatment these inhibitors become ine...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009617666170330112842

    authors: Agarwal SM,Pal D,Gupta M,Saini R

    更新日期:2017-01-01 00:00:00

  • Antiandrogens in prostate cancer endocrine therapy.

    abstract::Prostate cancer is the most frequently diagnosed tumor in industrialized countries. Endocrine therapy, which is based on interference with androgen signaling is only palliative. Drugs used in prostate cancer therapy are luteinizing hormone releasing hormone (LHRH) agonists and antiandrogens. Application of LHRH agonis...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009043332925

    authors: Culig Z,Bartsch G,Hobisch A

    更新日期:2004-08-01 00:00:00

  • Function and antagonism of beta3 integrins in the development of cancer therapy.

    abstract::The integrin family of cell surface receptors integrates cell-extracellular matrix interactions with the cell cytoskeleton and signalling across the cell membrane, resulting in an important role in cell adhesion, mobility and migration, proliferation, and survival. Changes in the number and identity of integrin recept...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800909788486713

    authors: Sheldrake HM,Patterson LH

    更新日期:2009-06-01 00:00:00

  • New strategies in the chemotherapy of leukemia: eradicating cancer stem cells in chronic myeloid leukemia.

    abstract::Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by the Philadelphia-positive chromosome deriving from a translocation between chromosomes 22 and 9. The oncogenic product of this aberrant chromosome is the constitutively active tyrosine kinase BCR-ABL that is responsible for leukemic cell growth,...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800912800673239

    authors: Stefanachi A,Leonetti F,Nicolotti O,Catto M,Pisani L,Cellamare S,Altomare C,Carotti A

    更新日期:2012-06-01 00:00:00

  • Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials.

    abstract::Bisphosphonates are the standard of care for preventing skeletal morbidity and treating hypercalcemia of malignancy in patients with bone metastases. Zoledronic acid (intravenous; 4 mg monthly) is approved to prevent skeletal-related events (SREs) in patients with bone metastases from several tumor types, and can impr...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800909789760267

    authors: Gnant M

    更新日期:2009-11-01 00:00:00

  • Malignant Glioma In Vitro Models: On the Utilization of Stem-like Cells.

    abstract::Recent publications on the molecular characterization of malignant glioma have had profound impact on the appreciation of tumoral heterogeneity within and between patients. Both these phenomena are implicated in the variability in clinical outcome between patients, as well as the inevitable recurrence of these tumors ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009616666160813191809

    authors: Balvers RK,Dirven CM,Leenstra S,Lamfers ML

    更新日期:2017-01-01 00:00:00

  • Peptidyl prolyl isomerase, Pin1 is a potential target for enhancing the therapeutic efficacy of etoposide.

    abstract::The peptidyl prolyl isomerase (Pin1) that induces cis-trans isomerization of the peptide bond involving serine/threonine-proline has recently been shown to regulate the activity of many phosphoproteins including the ones involved in damage response pathways. We investigated Pin1 as a potential target for enhancing the...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/156800911794519761

    authors: Mathur R,Chandna S,N Kapoor P,S Dwarakanath B

    更新日期:2011-03-01 00:00:00

  • Chronic vaccination with a therapeutic EGF-based cancer vaccine: a review of patients receiving long lasting treatment.

    abstract::Therapeutic vaccines continue to be one of the most active fields in cancer research. However, despite clear evidence of antitumor effect in laboratory animals, and despite the ability of current vaccine candidates to elicit tumor specific antibodies and T-cells in humans, objective responses in the clinical trials ar...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800911793743583

    authors: Gonzalez G,Crombet T,Lage A

    更新日期:2011-01-01 00:00:00

  • Recent advances in understanding hormonal therapy resistant prostate cancer.

    abstract::Androgen deprivation therapy has been the major treatment for advanced prostate cancer (PCa) and has shown to prolong life. However, remissions are temporary and patients almost inevitably progress to become castration-resistant prostate cancer (CRPC). CRPC is almost incurable even when treated with docetaxel that may...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800910791208544

    authors: Donkena KV,Yuan H,Young CY

    更新日期:2010-06-01 00:00:00

  • Matrix metalloproteinases as therapeutic targets in cancer.

    abstract::Degradation of extracellular matrix is crucial for malignant tumor growth, invasion, metastasis and angiogenesis. Matrix metalloproteinases (MMPs) are a family of zinc-dependent neutral endopeptidases collectively capable of degrading essentially all matrix components. Elevated levels of distinct MMPs can be detected ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009053765799

    authors: Vihinen P,Ala-aho R,Kähäri VM

    更新日期:2005-05-01 00:00:00

  • Voltage-dependent potassium channels Kv1.3 and Kv1.5 in human cancer.

    abstract::Membrane ion channels participate in cancerous processes such as proliferation, migration and invasion, which contribute to metastasis. Increasing evidence indicates that voltage-dependent K(+) (Kv) channels are involved in the proliferation of many types of cells, including tumor cells. Kv channels have generated imm...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/156800909790192400

    authors: Bielanska J,Hernández-Losa J,Pérez-Verdaguer M,Moline T,Somoza R,Ramón Y Cajal S,Condom E,Ferreres JC,Felipe A

    更新日期:2009-12-01 00:00:00

  • Targeting the STAT pathway in head and neck cancer: recent advances and future prospects.

    abstract::Head and neck cancer, the sixth most common type of cancer worldwide, is associated with a dismal prognosis that has minimally improved during the last few decades. Future advances in the treatment and prognosis of this fatal disease largely rely upon a better understanding of the molecular events that underlie tumor ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009043332736

    authors: Nikitakis NG,Siavash H,Sauk JJ

    更新日期:2004-12-01 00:00:00

  • Targeted histone deacetylase inhibition for cancer therapy.

    abstract::The histone deacetylase inhibitors are a new class of cytostatic agents that inhibit the proliferation of tumor cells in culture and in vivo by inducing cell cycle arrest, differentiation and/or apoptosis. Histone acetylation and deacetylation play important roles in the modulation of chromatin topology and the regula...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009043481560

    authors: Vigushin DM,Coombes RC

    更新日期:2004-03-01 00:00:00

  • Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases.

    abstract::Aurora kinases and cyclin-dependent kinases, which play critical roles in the cell cycle and are frequently overexpressed in a variety of tumors, have been suggested as attractive targets for cancer therapy. JNJ-7706621, a recently identified dual inhibitor of these kinases, is reported to induce cell cycle arrest, en...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/156800912801784839

    authors: Matsuhashi A,Ohno T,Kimura M,Hara A,Saio M,Nagano A,Kawai G,Saitou M,Takigami I,Yamada K,Okano Y,Shimizu K

    更新日期:2012-07-01 00:00:00

  • Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases.

    abstract::It has been estimated that greater than 35% of all human genes undergo alternative splicing. The process of alternative splicing is highly regulated and disruption of a splicing pattern can produce splice variants that have different functions. Certain splice variants that are associated with induction of cell death, ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009013334124

    authors: Mercatante DR,Sazani P,Kole R

    更新日期:2001-11-01 00:00:00

  • Anti-angiogenic targets in the treatment of advanced renal cell carcinoma.

    abstract::Drugs that target the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) pathways have revolutionized the treatment of patients with metastatic renal cell cancer (RCC). Patients with clear cell RCC often have mutations or silencing of the von Hippel Lindau gene leading to an accumulati...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800908786733450

    authors: Heng DY,Bukowski RM

    更新日期:2008-12-01 00:00:00

  • Advances in In-Silico based Predictive In-Vivo Profiling of Novel Potent β-Glucuronidase Inhibitors.

    abstract:BACKGROUND:Intestinal β-glucuronidase enzyme has a significant importance in colorectal carcinogenesis. Specific inhibition of the enzyme helps prevent immune reactivation of the glucuronide- carcinogens, thus protecting the intestine from ROS (Reactive Oxidative Species) mediatedcarcinogenesis. OBJECTIVES:Advancement...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/1568009619666190320102238

    authors: Yousuf M

    更新日期:2019-01-01 00:00:00

  • TXNL1 induces apoptosis in cisplatin resistant human gastric cancer cell lines.

    abstract::Cisplatin is one of the most commonly used drugs in the treatment of gastric cancer. However, drug resistance is a major obstacle for effective treatment and originates in multiple mechanisms such as enhanced DNA repair and anti-apoptosis. Our previous results demonstrated that XRCC1 was a key regulator of cisplatin i...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/1568009614666141028094612

    authors: Ni P,Xu W,Zhang Y,Chen Q,Li A,Wang S,Xu S,Zhou J

    更新日期:2015-01-01 00:00:00

  • Tubulin folding pathways: implication in the regulation of microtubule dynamics.

    abstract::As microtubules are essential in many cell functions, they have been used as a target of a variety of anticancer drugs that are grouped as stabilizing (taxanes) and destabilizing (vinca-alkaloids, colchicinoids) microtubule agents. It appears clearly now that the dynamic behaviour more than modifications of microtubul...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800907783220426

    authors: Beghin A,Galmarini CM,Dumontet C

    更新日期:2007-12-01 00:00:00

  • Mechanisms used by human papillomaviruses to escape the host immune response.

    abstract::The greatest risk factor for the development of cervical and other cancers that have been linked to the human papillomavirus (HPV) family is the persistence of the virus. To persist for the decades required to develop HPV-related cancers, the virus must escape host immunity. HPV is a simple DNA virus that has evolved ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800907780006869

    authors: Kanodia S,Fahey LM,Kast WM

    更新日期:2007-02-01 00:00:00

  • Human mesenchymal stem cells (hMSCs) as targets of DNA damaging agents in cancer therapy.

    abstract::Human mesenchymal stem cells (hMSCs) consist of cells that can differentiate into mesenchymal tissues, including osteoblasts, adipocytes and chondrocytes. hMSCs constitute a particular stem cell niche in the stromal compartment of the bone marrow, and also play a role in maintaining the normal function of haematopoiet...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/156800910791208553

    authors: Cruet-Hennequart S,Prendergast AM,Barry FP,Carty MP

    更新日期:2010-06-01 00:00:00

  • UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase- 6 (pp-GalNAc-T6): Role in Cancer and Prospects as a Drug Target.

    abstract::UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosaminyl transferase-6 (pp-GalNAc-T6) is a member of the N-acetyl-D-galactosamine transferase family. It catalyzes the addition of N-acetyl-D-galactosamine to proteins, often the first step in O-glycosylation of proteins. Glycosylated proteins play important role...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章,评审

    doi:10.2174/1568009616666160922102641

    authors: Banford S,Timson DJ

    更新日期:2017-01-01 00:00:00

  • Targeting NUPR1 for Cancer Treatment: A Risky Endeavor.

    abstract::NUPR1 is a transcription factor that has attracted great attention because of its various roles in cancer. Several studies were carried out to determine its molecular targets and mechanism of action to develop novel therapies against cancer. Here, we shed light on the role of NUPR1 in different types of cancer. NUPR1 ...

    journal_title:Current cancer drug targets

    pub_type: 杂志文章

    doi:10.2174/1568009620666200703152523

    authors: Mansour SMA,Ali SA,Nofal S,Soror SH

    更新日期:2020-01-01 00:00:00